

## Supplementary Material for

### **Solid-state NMR, X-ray diffraction and theoretical studies of neutral mononuclear molecular bis(triphenylphosphine)silver(I) mono-carboxylate and nitrate systems**

Simon Grabowsky,<sup>a,\*</sup> Allan H. White,<sup>b,#</sup> Peter C. Healy,<sup>c</sup> Kim M. Lapere,<sup>d</sup> Seik Weng Ng,<sup>e</sup>  
Brian W. Skelton,<sup>b</sup> Duncan A. Wild,<sup>b</sup> Graham A. Bowmaker,<sup>f,\*</sup> and John V. Hanna<sup>g,\*</sup>

<sup>a</sup> University of Bern, Department of Chemistry and Biochemistry, Freiestrasse 3, 3012 Bern, Switzerland

<sup>b</sup> University of Western Australia, School of Molecular Sciences, 35 Stirling Highway, Perth, WA 6009, Australia

<sup>c</sup> Griffith University, School of Environment and Science, 170 Kessels Road, Nathan, 4111 Queensland, Australia

<sup>d</sup> University of New South Wales, School of Chemistry, Sydney, 2052 New South Wales, Australia

<sup>e</sup> University of Malaya, Department of Chemistry, 50603 Kuala Lumpur, Malaysia

<sup>f</sup> University of Auckland, School of Chemical Sciences, Private Bag 92019, Auckland, New Zealand

<sup>g</sup> University of Warwick, Department of Physics, Gibbet Hill Rd., Coventry CV4 7AL, U.K.

# Professor Allan H. White is deceased.

\* Corresponding authors e-mail addresses: [simon.grabowsky@dcb.unibe.ch](mailto:simon.grabowsky@dcb.unibe.ch),  
[g.bowmaker@auckland.ac.nz](mailto:g.bowmaker@auckland.ac.nz), [j.v.hanna@warwick.ac.uk](mailto:j.v.hanna@warwick.ac.uk)

**Table S1.** Crystallographically established silver(I) atom environments in [(Ph<sub>3</sub>P)<sub>2</sub>Ag(O<sub>2</sub>XY)] complexes. (Relevant copper(I) analogues are also included for comparison.)

Anion (/mol.)	Ag-P/Å	Ag-O/Å	P-Ag-P/°	O-Ag-O/°	P-Ag-O/°	
(a) <i>Silver(I) complexes</i>						
O <sub>2</sub> CCH <sub>2</sub> Ph ( <b>1</b> ) <sup>a</sup>	2.432(1)	2.436(1)	128.9(1)	53.4(1)	106.6(1)	
	2.442(1)	2.458(1)			-118.3(1)	
O <sub>2</sub> CCHPh <sub>2</sub> ( <b>2</b> ) <sup>a</sup>	2.438(1)	2.441(2)	126.2(1)	52.8(1)	98.1(1)	
	2.465(1)	2.484(3)			-120.2(1)	
O <sub>2</sub> CC(CH <sub>3</sub> ) <sub>3</sub> ( <b>3</b> ) <sup>a</sup>	2.440(2)	2.392(4)	131.4(1)	53.8(1)	106.9(1)	
	2.458(2)	2.499(4)			-118.3(1)	
O <sub>2</sub> CCH <sub>2</sub> C(CH <sub>3</sub> ) <sub>3</sub> ( <b>4</b> )/ <sup>a</sup> 1	2.416(1)	2.384(3)	129.7(1)	53.5(1)	104.5(1)	
	2.425(1)	2.497(2)			-116.0(1)	
	/2	2.439(1)	2.410(3)	125.8(1)	53.1(1)	111.1(1)
		2.450(1)	2.494(3)			-116.5(1)
O <sub>2</sub> CCH <sub>3</sub> ( <b>6</b> )/1 <sup>b</sup> (anhydrate)	2.4332(8)	2.420(2)	129.62(3)	53.33(7)	106.03(7)	
	2.4483(8)	2.438(2)			-114.83(7)	
	/2	2.4264(8)	2.379(3)	124.13(3)	52.3(1)	102.0(1)
		2.4608(8)	2.510(3)			-125.61(8)
(·EtOH·H <sub>2</sub> O) ( <b>7</b> )/1 <sup>c</sup>	2.4461(8)	2.438(2)	127.72(3)	52.8(1)	110.75(8)	
	2.4490(8)	2.451(3)			-115.25(7)	
	/2	2.4063(8)	2.431(2)	127.96(3)	53.5(1)	103.10(9)
		2.4582(8)	2.449(3)			-122.50(7)
O <sub>2</sub> CC(OH)CH <sub>3</sub> ( <b>8</b> ) <sup>d</sup>	2.4345(9)	2.425(3)	126.15(3)	51.3(1)	104.7(1)	
	2.4671(9)	2.508(4)			-126.5(1)	
O <sub>2</sub> CCF <sub>3</sub> ( <b>5α</b> ) <sup>e</sup> (orthorhombic)	2.423(1)	2.526(3)	142.18(4)	51.6(1)	97.13(9)	
	2.445(1)	2.542(4)			-112.41(9)	
	( <b>5β</b> ) <sup>a</sup> (monoclinic)	2.4367(7)	2.420(3)	129.35(5)	47.18(9)	99.73(7)
		2.4542(8)	2.894(4)			-126.97(8)
O <sub>2</sub> CH <sup>f</sup>	2.426(1)	2.425(3)	127.37(3)	52.4(1)	112.53(9), 114.36(8)	
O <sub>2</sub> CH(·HCO <sub>2</sub> H) <sup>f</sup>	2.426(2)	2.550(7)	147.86(7)	49.5(2)	104.26(5)	
		2.713(8)			104.84(5)	

NO <sub>3</sub> ( <b>9α</b> ) (298 K) <sup>a</sup> (unsolvated)	2.4379(6)	2.460(2)	138.26(2)	49.77(5)	100.42(4)
	2.4357(7)	2.648(2)			-111.55(4)
(200 K) <sup>a</sup>	2.4360(5)	2.4551(13)	138.58(1)	50.26(4)	100.11(3)
	2.4391(5)	2.6431(16)			-110.96(3)
(120 K) <sup>g</sup>	2.4254(6)	2.4287(14)	138.14(2)	50.22(4)	99.38(4)
	2.4286(6)	2.6711(14)			-110.97(4)
( <b>10</b> ) <sup>h</sup> (triclinic, benzene solvate)	2.435(1)	2.463(2)	139.4(1)	50.4(1)	96.7(1)
	2.416(1)	2.572(2)			-114.9(1)
( <b>11α</b> ) <sup>a</sup> (triclinic, toluene solvate)	2.4232(5)	2.468(2)	138.10(2)	51.35(5)	99.60(4)
	2.4366(5)	2.550(2)			-114.08(4)
( <b>11β</b> ) <sup>a</sup> (monoclinic, toluene solvate)	2.411(3)	2.451(7)	135.85(9)	50.5(2)	98.4(2)
	2.430(2)	2.541(7)			-114.5(2)
(b) <i>Copper(I) complexes</i>					
O <sub>2</sub> CH <sup>i</sup>	2.247(1)	2.226(3)	128.3(4)	58.05(8)	110.3(1), 114.6(1)
O <sub>2</sub> CCH <sub>3</sub> <sup>j</sup>	2.224(2), 2.232(2)	2.167(4), 2.227(3)	133.29(1)	60.3(1)	104.6(1), -116.4(1)
O <sub>2</sub> CCH <sub>2</sub> F <sup>k</sup>	2.222(3), 2.232(3)	2.144(6), 2.363(7)	135.0(1)	58.4(2)	101.7(2), -117.0(2)
O <sub>2</sub> CCHF <sub>2</sub> <sup>k</sup>	2.219(2), 2.234(2)	2.118(4), 2.465(6)	135.8(1)	56.7(2)	99.3(2), -117.0(2)
O <sub>2</sub> CCF <sub>3</sub> <sup>k</sup>	2.228(2), 2.235(2)	2.113(4), 2.545(5)	136.7(1)	55.4(1)	98.6(1), -116.3(1)
O <sub>2</sub> NO <sup>l</sup>	2.231(4)	2.205(2)	130.9(1)	57.4(1)	108.3(1), 114.5(1)
O <sub>2</sub> NO <sup>m,†</sup>	2.252(3), 2.252(3)	2.217(9), 2.184(9)	128.0(1)	56.2(4)	104.9(3), -117.2(3)

<sup>a</sup> This work; <sup>b</sup> ref. 24; <sup>c</sup> ref. 25; <sup>d</sup> ref. 26; <sup>e</sup> ref. 27; <sup>f</sup> ref. 5(a); <sup>g</sup> ref. 35(c); <sup>h</sup> ref. 36; <sup>i</sup> ref. 30; <sup>j</sup> ref. 31(c); <sup>k</sup> ref. 32; <sup>l</sup> ref. 33(c); <sup>m</sup> ref. 33(d). <sup>†</sup> a (*p*-tol)<sub>3</sub>P adduct.

**Table S2.** Unit cell descriptors of [(Ph<sub>3</sub>P)<sub>2</sub>M(O<sub>2</sub>XY)] (unsolvated)

M(O <sub>2</sub> X,Y) <sup>Ref</sup>	CCDC code*	Space group	T(K)	<i>a</i> (Å)	<i>b</i> (Å)	<i>c</i> (Å)	α (°)	β (°)	γ (°)	<i>V</i> (Å <sup>3</sup> )
Mononuclear forms										
Cu(O <sub>2</sub> CH) <sup>a</sup>	BOMFUE	<i>C2/c</i>	RT	24.582(9)	9.100(5)	15.469(7)		116.10(10)		3107
Cu(O <sub>2</sub> CCH <sub>3</sub> ) <sup>b</sup>	ACPHCU02	<i>P2<sub>1</sub>/c</i>	193	18.085(5)	10.977(2)	17.979(5)		115.62(2)		3218
Cu(O <sub>2</sub> CCF <sub>3</sub> ) <sup>c</sup>	WEPKAD	<i>P2<sub>1</sub>/a</i>	RT	18.123(9)	11.357(5)	19.340(10)		122.04(6)		3374
Cu(O <sub>2</sub> N) <sup>d</sup>	HIBPUD	<i>C2/c</i>	RT	24.443(9)	9.102(2)	15.356(5)		116.01(3)		3070
Cu(O <sub>2</sub> NO) <sup>e</sup>	NITPPC01	<i>C2/c</i>	RT	24.558(5)	9.185(3)	15.420(3)		116.43(2)		3115
Ag(O <sub>2</sub> CH) <sup>f</sup>	KIXCAV02	<i>C2/c</i>	RT	24.884(3)	9.189(1)	15.283(6)		116.05(2)		3140
Ag(O <sub>2</sub> CCH <sub>3</sub> ) <sup>g</sup>	ACPSAG01	<i>P1</i> <sup>-</sup>	RT	10.078(1)	13.775(1)	24.167(3)	92.05(1)	90.67(1)	100.19(1)	3299
Ag(O <sub>2</sub> CCF <sub>3</sub> ) <sup>h</sup>	NOZPIB	<i>Pbca</i>	153	16.964(3)	18.972(4)	21.063(3)				6779
Ag(O <sub>2</sub> CCF <sub>3</sub> ) <sup>i</sup>	NOZPIB01	<i>C2/c</i>	150	23.403(14)	12.0965(7)	23.3957(14)		94.0440(10)		6607
Ag(O <sub>2</sub> NO) <sup>i</sup>	HIPVEH01	<i>P2<sub>1</sub>/c</i>	150	11.908(2)	18.364(2)	14.761(2)		101.12(1)		3167
Ag(O <sub>2</sub> N) <sup>j</sup>	DUSZOG02	<i>P1</i> <sup>-</sup>	120	11.682(2)	11.833(2)	13.569(2)	102.64(1)	112.14(1)	105.65(1)	1561
Ag(O <sub>2</sub> COH) <sup>k</sup>	OTAHUN	<i>P1</i> <sup>-</sup>	100	10.2351(3)	11.9944(3)	13.8661(3)	85.949(2)	87.989(2)	65.093(3)	1540
Ag(O <sub>2</sub> NO)(C <sub>6</sub> H <sub>6</sub> ) <sup>l</sup>	SAYZAT	<i>P1</i> <sup>-</sup>	RT	12.279(1)	16.260(1)	11.134(1)	102.51(1)	114.28(1)	101.79(1)	1868
(C <sub>7</sub> H <sub>8</sub> ) <sup>i</sup>	This work	<i>P1</i> <sup>-</sup>	200	11.2434(4)	12.3381(6)	16.2534(6)	106.398(4)	96.842(3)	115.208(4)	1881

	This work	$P2_1/c$	RT	16.637(2)	19.265(4)	12.1100(13)	102.661(9)	3787
Binuclear forms								
$\text{Cu}(\mu\text{-O.CO.OH})_2\text{Cu}^l$	ZIMNAK	$P2_12_12$	RT	14.721(2)	21.113(2)	9.2130(10)		3135
$\text{Ag}(\mu\text{-O.NO}_2)_2\text{Ag}^m$	WANFAS	$P2_12_12$	178	14.904(5)	23.169(7)	9.262(3)		3198
$\text{Ag}(\mu\text{-O.CO.OH})_2\text{Ag}^k$	OTAHEX	$P2_12_12$	RT	14.990(2)	23.435(7)	9.296(3)		3266

---

\*Cambridge Structural Database, 2019. <sup>a</sup> Ref. 30; <sup>b</sup> ref. 31(c); <sup>c</sup> ref. 32; <sup>d</sup> ref. 59; <sup>e</sup> ref. 33(b); <sup>f</sup> ref. 5; <sup>g</sup> ref. 24; <sup>h</sup> ref. 27; <sup>i</sup> this work; <sup>j</sup> ref. 35(c); <sup>k</sup> ref. 23; <sup>l</sup> ref. 36; <sup>m</sup> ref. 37.


**Table S3.**  $^{31}\text{P}$  NMR parameters measured from the 1D  $^{31}\text{P}$  CPMAS and 2D  $^{31}\text{P}$ - $^{31}\text{P}$  CPCOSY MAS NMR data of **1**, **2**, **3**, **4**, **5 $\beta$** , **9 $\alpha$** , **11 $\alpha$**  and **11 $\beta$**  reported in this work, compared with values measured from previously reported bidentate carboxylate systems.

Compound	$\delta(^{31}\text{P})/\text{ppm}$ ( $\pm 0.2$ ppm)	$^1J(^{107/109}\text{Ag}, ^{31}\text{P})/\text{Hz}$ <sup>a</sup> ( $\pm 3$ Hz)	$^2J(^{31}\text{P}, ^{31}\text{P})/\text{Hz}$ ( $\pm 2$ Hz)	Ref.
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_2\text{Ph})]$ <b>1</b>	5.9 8.5	443 439	125	this work
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCHPh}_2)] \cdot \text{EtOH}$ <b>2</b>	3.8 11.0	414 470	125	this work
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CC}(\text{CH}_3)_3)]$ <b>3</b> (molecule 1, larger component from disorder)	7.1 8.5	426 455	124	this work
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CC}(\text{CH}_3)_3)]$ <b>3</b> (molecule 2, smaller component from disorder)	7.5 10.6	422 438	140	
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_2\text{C}(\text{CH}_3)_3)]$ <b>4</b> (molecule 1)	6.3 8.8	426 455	125	this work
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_2\text{C}(\text{CH}_3)_3)]$ <b>4</b> (molecule 2)	4.4 7.6	419 423	134	
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCF}_3)]$ , <b>5<math>\beta</math></b>	9.0 11.4	461 506	112	this work
$[(\text{PPh}_3)_2\text{AgNO}_3]$ <b>9<math>\alpha</math></b>	7.5 9.3	489 492	127	this work
$[(\text{PPh}_3)_2\text{AgNO}_3] \cdot \text{toluene}$ <b>11<math>\alpha</math></b>	6.8 13.7	482 505	126	this work
$[(\text{PPh}_3)_2\text{AgNO}_3] \cdot \text{toluene}$ <b>11<math>\beta</math></b>	6.0 10.5	471 510	136	this work
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{C}_6\text{H}_7\text{O}_7)] \cdot \text{EtOH}$ dihydrogen citrate	7.6 12.9	412 501	134	9
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{C}(\text{OH})\text{CHCH}_2)]$ lactate (molecule 1)	2.5 9.0	390 478	144	26
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{C}(\text{OH})\text{CHCH}_2)]$ lactate (molecule 2)	4.1 7.1	389 471	144	
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CH})]$ formate				6
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_3)]$ acetate (molecule 1)	4.7 9.5	385 459	146	65
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_3)]$ acetate (molecule 1)	6.3 9.1	420 439	131	
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_3)] \cdot \text{H}_2\text{O} \cdot 0.5\text{EtOH}$ acetate (molecule 1)	7.0 9.8	382 487	133	25
$[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_3)] \cdot \text{H}_2\text{O} \cdot 0.5\text{EtOH}$ acetate (molecule 1)	16.23 17.78	426 427	133	
$[[(\text{PPh}_3)_2\text{Ag}(\text{O}_2\text{CNC}_5\text{H}_4)]_2]_n$ nicotinate (molecule 1)	6.5 10.3	433 457	140	b
$[[(\text{PPh}_3)_2\text{Ag}(\text{O}_2\text{CNC}_5\text{H}_4)]_2]_n$ nicotinate (molecule 1)	7.3 9.2	437 439	135	
$[(\text{PPh}_3)_2\text{Ag}(\text{O}_2\text{CC}_6\text{H}_4\text{OH})]_4$ hydroxybenzoate	7.3 9.7	416 451	125	c


<sup>a</sup> average value of  $^1J(^{107}\text{Ag}, ^{31}\text{P})$  and  $^1J(^{109}\text{Ag}, ^{31}\text{P})$  couplings.

<sup>b</sup> N. R. A Rahazat, R. A. Haque, S.-W. Ng, M.R. Razali, *J. Coord. Chem.* **2015**, *68*, 1317.


<sup>c</sup> M. Poyraz, C. N. Banti, N. Kourkoumelis, V. Dokorou, M. J. Manos, M. Simcic, S. Golic-Grdadolnik, T. Mavromoustakos, A. D. Giannoulis, I. I. Verginadis, K. Charalabopoulos, S. K. Hadjikakou, *Inorg. Chim. Acta* **2011**, *375*, 114.




**Figure S1.** 1D  $^{31}\text{P}$  CPMAS (F1 & F2 projections) and 2D  $^{31}\text{P}$ - $^{31}\text{P}$  CPCOSY MAS NMR data from previously reported carboxylate-based systems, (a)  $[(\text{Ph}_3\text{P})_2\text{AgO}_2\text{C}(\text{OH})\text{CHCH}_2]$  (lactate), (b)  $[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_3)]$  (acetate), (c)  $[(\text{Ph}_3\text{P})_2\text{Ag}(\text{O}_2\text{CCH}_3)] \cdot \text{H}_2\text{O} \cdot 0.5\text{EtOH}$  (acetate solvate), (d)  $[(\text{PPh}_3)_2\text{Ag}(\text{O}_2\text{CNC}_5\text{H}_4)]_n$  (nicotinate) and (e)  $[(\text{PPh}_3)_2\text{Ag}(\text{O}_2\text{CC}_6\text{H}_4\text{OH})]_4$  (hydroxybenzoate).




(a) compound 1




(b) compound 2




(c) compound **3**




(d) compound **4**



(e) compound **5β**



(f) compound **11α**



(g) compound **11β**

**Figure S2.**  $^{31}\text{P}$  CPMAS NMR spectra of compound **1**, **2**, **3**, **4**, **5β**, **11α** and **11β** and stick diagrams of the simulated spectra as the AB part of an ABX system.